Page 2 - கனடியன் காப்புரிமை அலுவலகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

IP Litigation 2020 Year In Review - Intellectual Property

Canmar 5 was a trend for a day or here to stay. This year, the Federal Court has seen increased attempts by litigants to resolve matters more expeditiously by way of dispositive motions. Summary judgment was granted in three cases 6 and two motions for default judgment were brought but dismissed based on insufficient evidence. ViiV Healthcare Company v. Gilead Sciences Canada, 8 the Court held that completion of discoveries is not a precondition to summary trial such that resolution may be sought at very early stages of the proceeding. We saw the Federal Court grant summary disposition to (a) dispose of claim construction argument,

Justice southcottJustice orilleyJustice kaneJustice nadonJustice mcveighJustice hughesJustice lafreniJustice pentneyJustice boswellJustice fuhrerJustice oreillyJustice rivoalenJustice royJustice grammondJustice mansonJustice webb

Office Actions: Options to consider when you need an extension of time to respond to the Patent Office | Smart & Biggar

The extensive amendments to the Patent Act and Patent Rules that came into force on October 30, 2019 have complicated the practice for responding to an Office Action (i.e. an.

Canadian patent officeService feesManual of patent office practicePatent office practice noticePatent officeOffice actionPatent actPatent rulesCanadian patentPatent office practicePractice noticeFriday januaryTuesday mayMonday mayVictoria dayThursday july

Federal Court Invalidates Janssen ZYTIGA® Patent - Intellectual Property

On January 14, 2021, the Federal Court issued a decision ( Janssen Inc. et al v. Apotex Inc. et al, 2021 FC 7) in the consolidated infringement action brought under s. 6(1) of the Patented Medicine (Notice of Compliance) (PM(NOC)) Regulations by Janssen against Apotex, Dr. Reddy s Laboratory, and Pharmascience. In this decision, the Court invalidated the asserted claims of Janssen s Canadian Patent 2,661,422 (the 422 Patent), which claimed the combined use of the two active ingredients found in Janssen s brand name drug ZYTIGA, abiraterone acetate and prednisone, in the treatment of prostate cancer. Concurrently, the Court dealt with Apotex counterclaim under s. 6(3) of the PM(NOC) Regulations to

Taro pharmaceuticals incSunovion pharmaceuticalsJanssen incFree worldCanadian patent officeCanada incSanofi synthelabo canada incApotex incFederal courtPatented medicineCanadian patentFree world trustAsserted claimsPatent examination noticeFederal court invalidates janssen zytiga xae patentIntellectual property

Mountain Valley MD erhält kanadisches Patent für seine Quicksome-Technologie

Mountain Valley MD erhält kanadisches Patent für seine Quicksome-Technologie
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Development of productsCompany websiteAspirations in range healthCanadian patent officeAdministration of vaccinesLeadership role in technology sectorCurrent pressCanadian cleverPatent applicantCanadian marketActive ingredientInfluential measureStudy dataFor administrationTime periodJohn hour

IRW-News: Mountain Valley MD Holdings Inc : Mountain Valley MD erhält kanadisches Patent für seine Quicksome-Technologie

IRW-News: Mountain Valley MD Holdings Inc : Mountain Valley MD erhält kanadisches Patent für seine Quicksome-Technologie
boersennews.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from boersennews.de Daily Mail and Mail on Sunday newspapers.